↓ Skip to main content

Cochrane Database of Systematic Reviews

Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals

Overview of attention for article published in Cochrane database of systematic reviews, March 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

blogs
1 blog
policy
1 policy source
twitter
30 X users
peer_reviews
2 peer review sites
facebook
3 Facebook pages
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
123 Mendeley
citeulike
1 CiteULike
Title
Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals
Published in
Cochrane database of systematic reviews, March 2016
DOI 10.1002/14651858.cd011745.pub2
Pubmed ID
Authors

Garry Taverny, Yanis Mimouni, Anne LeDigarcher, Philippe Chevalier, Lutgarde Thijs, James M Wright, Francois Gueyffier

Abstract

High blood pressure is an important public health problem because of associated risks of stroke and cardiovascular events. Antihypertensive drugs are often used in the belief that lowering blood pressure will prevent cardiac events, including myocardial infarction and sudden death (death of unknown cause within one hour of the onset of acute symptoms or within 24 hours of observation of the patient as alive and symptom free). To assess the effects of antihypertensive pharmacotherapy in preventing sudden death, non-fatal myocardial infarction and fatal myocardial infarction among hypertensive individuals. We searched the Cochrane Hypertension Specialised Register (all years to January 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (2016, Issue 1), Ovid MEDLINE (1946 to January 2016), Ovid EMBASE (1980 to January 2016) and ClinicalTrials.gov (all years to January 2016). All randomised trials evaluating any antihypertensive drug treatment for hypertension, defined, when possible, as baseline resting systolic blood pressure of at least 140 mmHg and/or resting diastolic blood pressure of at least 90 mmHg. Comparisons included one or more antihypertensive drugs versus placebo, or versus no treatment. Review authors independently extracted data. Outcomes assessed were sudden death, fatal and non-fatal myocardial infarction and change in blood pressure. We included 15 trials (39,908 participants) that evaluated antihypertensive pharmacotherapy for a mean duration of follow-up of 4.2 years. This review provides moderate-quality evidence to show that antihypertensive drugs do not reduce sudden death (risk ratio (RR) 0.96, 95% confidence interval (CI) 0.81 to 1.15) but do reduce both non-fatal myocardial infarction (RR 0.85, 95% CI 0.74, 0.98; absolute risk reduction (ARR) 0.3% over 4.2 years) and fatal myocardial infarction (RR 0.75, 95% CI 0.62 to 0.90; ARR 0.3% over 4.2 years). Withdrawals due to adverse effects were increased in the drug treatment group to 12.8%, as compared with 6.2% in the no treatment group. Although antihypertensive drugs reduce the incidence of fatal and non-fatal myocardial infarction, they do not appear to reduce the incidence of sudden death. This suggests that sudden cardiac death may not be caused primarily by acute myocardial infarction. Continued research is needed to determine the causes of sudden cardiac death.

X Demographics

X Demographics

The data shown below were collected from the profiles of 30 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 123 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 123 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 28 23%
Researcher 12 10%
Student > Ph. D. Student 12 10%
Student > Bachelor 12 10%
Student > Doctoral Student 8 7%
Other 13 11%
Unknown 38 31%
Readers by discipline Count As %
Medicine and Dentistry 49 40%
Nursing and Health Professions 14 11%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Psychology 4 3%
Biochemistry, Genetics and Molecular Biology 3 2%
Other 5 4%
Unknown 42 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 October 2023.
All research outputs
#1,226,218
of 25,380,192 outputs
Outputs from Cochrane database of systematic reviews
#2,599
of 12,620 outputs
Outputs of similar age
#20,575
of 312,907 outputs
Outputs of similar age from Cochrane database of systematic reviews
#72
of 236 outputs
Altmetric has tracked 25,380,192 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,620 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 36.8. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,907 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 236 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.